DIM Sartorius Stedim Biotech S.A.

250.73USD228.60 EUR · EPA+0.88%Mkt Cap: 24.40B USDP/E: 68.65

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; b…

Institutional holders11 on file

Key Statistics

Company
Market Cap24.40B USD
Enterprise Value26.79B USD
Revenue (TTM)3.36B USD
Gross Profit1.48B USD
Net Income (TTM)291.31M USD
Revenue/Share34.53 USD
Last Price250.73 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees10.5K
CountryFR
SectorHealthcare
IndustryMedical Instruments & Supplies
ISINFR0013154002
Valuation
P/E (Trailing)68.65
P/E (Forward)37.73
PEG1.63
EV/EBITDA29.24
EV/Revenue7.98
P/S7.27
P/B5.09
EPS (TTM)3.65 USD
EPS (Forward)6.65 USD
52W Range
164.5294% of range256.65
52W High256.65 USD
52W Low164.52 USD
Profitability
Gross Margin45.33%
Oper. Margin19.19%
EBITDA Margin27.29%
Profit Margin8.95%
ROE6.49%
ROA3.33%
ROIC6.11%
ROCE8.21%
Growth
Revenue Growth8.00%
Earnings Growth48.50%
Cash Flow & Leverage
Operating CF759.20M USD
CapEx (TTM)431.26M USD
FCF Margin8.84%
FCF Yield1.22%
Net Debt2.35B USD
Net Debt/EBITDA2.56
Net Debt/FCF7.90
Balance Sheet
Debt/Equity0.64
Current Ratio1.22
Quick Ratio0.46
Book Value/Sh49.27 USD
Cash/Share1.94 USD
Dividends
Fwd Div Rate0.76 USD
Trail. Div Rate0.00 USD
Div. Yield0.31%
5Y Avg Yield0.37%
Payout Ratio20.72%
Ex-Div DateMar 31, 2026
Pay Date—
Splits
Last Split6:1
Split DateMay 6, 2016
Analyst Consensus
Rating—
Target (Mean)274.20 USD
Upside (mean)+9.4%
Target Range239.10 USD – 308.20 USD
239.10+9.4% to mean308.20
# Analysts13
Ownership
Shares Out.97.31M
Float27.78M
Insiders71.50%
Institutions12.30%
Technical
SMA 50234.15 (+7.1%)
SMA 200202.22 (+24.0%)
Beta1.18
S&P 52W Chg12.00%
Avg Vol (30d)84.40K
Avg Vol (10d)75.28K
Technical Indicators
RSI (14)62.1
MACD3.5748
MACD Signal3.8963
MACD Hist.-0.3216
BB Upper254.06 USD
BB Middle245.24 USD
BB Lower236.43 USD
BB Width7.19%
ATR (14)6.424 USD
Vol Ratio (20d)1.46x

About Sartorius Stedim Biotech (EPA: DIM)

›

Sartorius Stedim Biotech (EPA: DIM) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 10,483 employees.

The shares were at 228.60 EUR on 19 November 2026, up 20.8% over 52 weeks. Its 52-week range is 150.00 EUR to 234.00 EUR: the price is 2.3% below the high and 52.4% above the low.

At a market capitalisation of 22.25B EUR, it trades at 68.6 times trailing earnings and 37.7 times forward earnings. The median trailing P/E of its 18 largest Medical Instruments & Supplies peers is 48.1, a premium of 43% for DIM. It pays a dividend yielding 0.31% (it pays out 21% of its earnings), against a median of 1.00% among the dividend payers in that peer group.

Sartorius Stedim Biotech reports return on equity of 6.5%, an operating margin of 19.2% and revenue up 8.0% year over year.

Its debt exceeds its cash by 2.14B EUR, a debt-to-equity ratio of 0.64. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 13 analysts cover the stock; their mean price target of 250.00 EUR is 9.4% above the current price. The next earnings report is expected on 23 February 2027.